Certolizumab Pegol 的小儿关节炎研究 (PASCAL)
一项多中心、开放标签研究,以评估 Certolizumab Pegol 在患有中度至重度活动性多关节病程幼年特发性关节炎 (JIA) 的儿童和青少年中的药代动力学、安全性和有效性
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
研究概览
详细说明
The overall study consists of a Screening Period of up to 4 weeks and an Open-Label Treatment Period which will continue until the approval of the marketing application for the Polyarticular-course Juvenile Idiopathic Arthritis (JIA) indication in the study participant's country or region or until further notice from UCB (approximately 4-6 years duration; depending on region). A Final Visit will be conducted 12 weeks after last dose of study medication. Overall, study visits will occur monthly during the first 6 months and every 2 months afterwards. All patients will receive active treatment with Certolizumab Pegol. The dose will depend on actual weight. Home dosing will be allowed between study visits.
If less than 50 % of the study population achieves an adequate response to the treatment (American College of Rheumatology Pediatric 30 % (PedACR30) response) at Week 16, the study will be entirely discontinued.
研究类型
注册 (实际的)
阶段
- 第三阶段
扩展访问
联系人和位置
学习地点
-
-
-
Moscow、俄罗斯
- Ra0043 41
-
Moscow、俄罗斯
- Ra0043 43
-
Saint Petersburg、俄罗斯
- Ra0043 40
-
Tolyatti、俄罗斯
- Ra0043 42
-
-
-
-
-
Calgary、加拿大
- Ra0043 21
-
Montreal、加拿大
- Ra0043 22
-
Toronto、加拿大
- Ra0043 20
-
-
-
-
-
Mexico City、墨西哥
- Ra0043 32
-
Monterrey、墨西哥
- Ra0043 30
-
México、墨西哥
- Ra0043 31
-
San Luis Potosí City、墨西哥
- Ra0043 33
-
-
-
-
-
Curitiba、巴西
- Ra0043 15
-
Porto Alegre、巴西
- Ra0043 14
-
São Paulo、巴西
- Ra0043 12
-
-
-
-
-
Santiago、智利
- Ra0043 60
-
-
-
-
Arkansas
-
Little Rock、Arkansas、美国、72202
- Ra0043 71
-
-
California
-
Los Angeles、California、美国、90027-6062
- Ra0043 79
-
San Francisco、California、美国、94143
- Ra0043 84
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- Ra0043 83
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- Ra0043 81
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Ra0043 82
-
Chicago、Illinois、美国、60637
- Ra0043 90
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Ra0043 75
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- Ra0043 80
-
Livingston、New Jersey、美国、07039
- Ra0043 77
-
-
New York
-
New Hyde Park、New York、美国、11042
- Ra0043 85
-
New York、New York、美国、10032
- Ra0043 87
-
-
North Carolina
-
Charlotte、North Carolina、美国、28203
- Ra0043 74
-
Durham、North Carolina、美国、27710
- Ra0043 76
-
-
Ohio
-
Avon、Ohio、美国、44011
- Ra0043 70
-
Cincinnati、Ohio、美国、45229
- Ra0043 73
-
Cleveland、Ohio、美国、44109
- Ra0043 78
-
Cleveland、Ohio、美国、44195
- Ra0043 95
-
Columbus、Ohio、美国、43205-2694
- Ra0043 86
-
-
Oregon
-
Portland、Oregon、美国、97227
- Ra0043 89
-
-
-
-
-
Buenos Aires、阿根廷
- RA0043 2
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2)
- Study participants must weigh ≥10 kg (22lb) at Baseline (Visit 2)
- Study participants must have had onset of signs and symptoms consistent with a diagnosis of Juvenile Idiopathic Arthritis (JIA) (according to the International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at least 6 months prior to Baseline (Visit 2). Eligible JIA categories include: polyarthritis rheumatoid factor-positive, polyarthritis rheumatoid factor-negative, extended oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis (ERA)
- Study participants must have active polyarticular-course disease, defined as ≥5 joints with active arthritis at Screening and at Baseline
- Study participants must have had an inadequate response to, or intolerance to, at least 1 disease-modifying antirheumatic drug (DMARD) (nonbiologic or biologic). For example, study participant had prior inadequate response to methotrexate (MTX) (based on the Investigator's clinical judgment)
- If the study participant is using MTX, then the study participant must have been on MTX for a minimum of 3 months at Screening. In addition, the dose must have been stable for at least 1 month before Screening at ≥10 to ≤15 mg/m^2 per week. If the study participant is not using MTX, then the treatment must have been previously withdrawn for documented reasons of intolerability or inadequate response
- If the study participant is using oral corticosteroid therapy, the dose must have been stable for at least 7 days prior to the Baseline arthritis assessment at a maximum dose of 10 mg or 0.2 mg/kg prednisone (or equivalent) per day, whichever is the smaller dose
Exclusion Criteria:
- Study participant has previously been exposed to more than 2 biologic agents
- Study participant previously failed to respond to treatment with more than one tumor necrosis factor alpha (TNFα) antagonist drug
- Study participant is currently receiving or has received any experimental (biological or nonbiological) therapy (within or outside a clinical study) in the 3 months or 5 half-lives prior to Baseline (Visit 2), whichever is longer
- Study participant had previous treatment with a biological therapy for juvenile idiopathic arthritis (JIA) that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
- Study participant previously participated in this study or has previously been treated with CZP (whether in a study or not)
- Study participant has a history of systemic JIA, with or without systemic features
- Study participant has a secondary, noninflammatory type of rheumatic disease or of joint pains (eg, fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study medication
- Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, inflammatory bowel disease-related)
- Study participant has active uveitis or a history of active uveitis within the preceding 6 months
- Study participant has current, chronic or recurrent clinically significant infections
- Study participant has a current sign or symptom which may indicate infection (eg, fever, cough), a history of chronic or recurrent infections within the same organ system (more than 3 episodes requiring antibiotics/antivirals during the 12 months prior to Screening [Visit 1]), had a recent (within the 6 months prior to Screening [Visit 1]) serious or life-threatening infection (including herpes zoster), or is at a high risk of infection in the Investigator's opinion (eg, study participants with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections or permanently bed-ridden or wheelchair bound)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Certolizumab Pegol
Active treatment with Certolizumab Pegol; dose adjustment is based on weight. |
CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution. Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range. Reduced CZP regimen (after implementation of protocol amendments 4 and 5):
其他名称:
CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution. Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range. Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16
大体时间:Week 16
|
Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per milliliter (ug/ml). |
Week 16
|
|
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48
大体时间:Week 48
|
Certolizumab Pegol (CZP) plasma concentration level was measured in ug/mL. |
Week 48
|
|
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16
大体时间:Week 16
|
Number of participants with anti-CZP antibodies were reported. |
Week 16
|
|
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48
大体时间:Week 48
|
Number of participants with anti-CZP antibodies were reported. |
Week 48
|
|
Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study
大体时间:From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
|
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in deaths, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect and other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. |
From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of the Investigational Medicinal Product (IMP) During the Study
大体时间:From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
|
An AE is any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not related to the IMP. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. TEAEs leading to permanent withdrawal of the IMP during the study were reported in this outcome measure. |
From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants Meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16
大体时间:Week 16
|
PedACR30-at least 30% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:
|
Week 16
|
|
Percentage of Participants Meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16
大体时间:Week 16
|
PedACR50- at least 50% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:
|
Week 16
|
|
Percentage of Participants Meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16
大体时间:Week 16
|
PedACR70- at least 70% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:
|
Week 16
|
|
Percentage of Participants Meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16
大体时间:Week 16
|
PedACR90- at least 90% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:
|
Week 16
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- RA0043
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 共享时间框架
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 共享访问标准
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.